|Some of these runners are still not done|
|Monday, 20 September 2010 04:33|
Here now is our opportunity to reiterate some of the solid companies that we've covered recently- especially since they have treated our readers and investors well. Its important to note that some of these runners are still not done, so keep a close eye because there is definitely more to come.
Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA) - This stock has been on fire since their $18M direct offering back in August, up roughly 40% since the lows in August. We began coverage on ALXA back in July and have updated subscribers about ALXA along the way. This stock still has more room to climb up until their PDUFA date for AZ-004 on October 11th, 2010. See our original report for all the details: http://biomedreports.com/articles/most-popular/46946-october-fda-decision-due-for-alexza-pharmaceuticals.html
Cleveland BioLabs, Inc.(Public, NASDAQ:CBLI) - Shares of CBLI have been climbing since we told our subscribers that the company was in line for some substantial government contracts. The stock was trading at $3.81at the time but it saw a high of $5.75 on Friday after the company was awarded a $45 million contract (including options), from the United States Department of Defense (DoD) Chemical Biological and Medical Systems (CBMS) Medical Identification and Treatment Systems (MITS) to develop and stockpile their CBLB502 drug as a medical radiation countermeasure.
This, and the fact that the stock should be heading even higher from here, should be of no surprise to our readers after Cleveland's Biolabs' CEO & President, Michael Fonstein told BioMedReports that his company was in line for contracts with multiple components. The company will host a conference call at 10:00 a.m. EDT today to discuss recent corporate developments and a live webcast of the conference call will be available on the Cleveland BioLabs web site at cbiolabs.com.
If you want to read more about why we are so bullish regarding CBLI, we invite you to start here. We believe strongly that this company will not be trading at these new higher levels for very long: http://biomedreports.com/articles/most-popular/51958-cleveland-biolabs-well-positioned-as-a-government-award-candidate.html
Chelsea Therapeutics International (NASDAQ:CHTP) - This stock went crazy on Friday, after a mention on CNBC by Peter Navarro (video linked below) sent shares to an intra-day high of $5.75!
Based on their recent presentation at Rodman and Renshaw, CEO Dr. Simon Pedder reiterated that results will be out at the end of September.
Kraig Biocraft Laboratories (OTC:KBLB) has been a surprise hit of these past two weeks. We first told our subscribers about this company which is dedicated to the development of Spider silk-based material, one of the strongest and most resilient fibers known to mankind back when it was trading at $.02.
Kraig Biocraft has called a press conference later this month to discuss developments in its laboratory. As a matter of fact, just this morning, the company announced that they anticipate releasing more details about that upcoming press conference later this week. Given all the recent hype, it is our belief Kraig Biocraft will make a significant announcements at that time. The stock has seen highs of $.19 and it closed at just under $.14 on Friday, but could go much higher in the weeks ahead.
Our original alert about the company can be read here: http://biomedreports.com/articles/most-popular/52582-transgenic-silkworms-could-spin-big-profits.html
Finally, when we broke the story that BMP Sunstone (NASDAQ:BJGP) had received a buy-out offer from a private company a few weeks ago, the stock was trading for just above $5. The stock is trading over $8 with even louder rumors about that pending buy-out circling the Street. Since our call, BMP Sunstone has made Smart Trend's list of top five companies in the pharmaceuticals industry as measured by relative performance.
Disclosure: Long CBLI, CHTP